length
paper
j
u
r
n
l
p
r
e
p
r
f
highlight
clear
expert
consensu
guidelin
treat
develop
riskadapt
treatment
approach
accord
ill
sever
strategi
effect
symptom
allevi
chest
ct
recoveri
strategi
use
effici
approach
patient
background
clear
expert
consensu
guidelin
treat
coronaviru
diseas
object
studi
investig
shortterm
effect
riskadapt
treatment
strategi
patient
collect
medic
record
patient
analysi
divid
patient
mild
moder
sever
group
riskadapt
treatment
approach
given
accord
ill
sever
result
twelv
patient
mild
group
moder
group
nonsever
group
patient
sever
group
end
first
two
week
admiss
clinic
manifest
complet
despear
patient
nonsever
group
patient
sever
group
group
satisfi
chest
ct
imag
recoveri
includ
patient
nonsever
group
patient
sever
group
recov
least
whole
leision
first
week
recov
least
second
week
respect
signific
differ
rna
clearanc
two
group
also
signific
differ
level
igg
antibodi
product
two
group
case
discharg
hospit
patient
die
time
clinic
analysi
conclus
riskadapt
treatment
strategi
associ
signific
clinic
manifest
allevi
clinic
imag
recoveri
sever
patient
earli
shortterm
use
lowdos
methylprednisolon
benefici
delay
rna
clearanc
influenc
igg
antibodi
product
j
u
r
n
l
p
r
e
p
r
f
novel
coronavirusassoci
pneumonia
name
coronaviru
diseas
began
spread
wuhan
china
decemb
becom
global
public
health
crisi
march
total
cumul
confirm
patient
cumul
death
china
accord
report
total
confirm
patient
death
outsid
china
limit
clinic
data
indic
associ
high
incid
intens
care
unit
icu
admiss
high
mortal
howev
clear
expert
consensu
guidelin
treat
develop
riskadapt
treatment
approach
accord
ill
sever
object
studi
investig
shortterm
effect
riskadapt
treatment
strategi
clinic
manifest
allevi
clinic
imag
recoveri
rna
clearanc
retrospect
studi
collect
medic
record
patient
analysi
patient
admit
unit
total
bed
clinic
characterist
includ
patient
age
sex
first
clinic
symptom
day
onset
symptom
hospit
respiratori
rate
heart
rate
oxygen
satur
etc
laboratori
paramet
includ
test
blood
routin
liver
kidney
function
coagul
creactiv
protein
procalcitonin
peripher
blood
percentag
level
igm
antibodi
etc
nasal
pharyng
swab
specimen
collect
detect
rna
test
realtim
reversetranscriptasepolymerasechainreact
rtpcr
least
three
time
within
week
divid
confirm
patient
three
type
mild
mild
respiratori
symptom
pulmonari
imag
comput
tomographi
ct
show
obviou
mild
pneumonia
moder
respiratori
symptom
fever
cough
pulmonari
ct
indic
typic
coronaviru
pneumonia
overal
lesion
less
howev
moder
patient
stabl
vital
sign
oxygen
without
oxygen
support
sever
least
clinic
featur
includ
reapiratori
rate
breathsminut
rest
oxygen
satur
without
oxygen
support
arteri
oxygen
partial
pressurefract
inspir
oxygen
mmhg
total
lesion
chest
ct
rapid
progress
next
hour
evalu
two
physician
two
radiologist
riskadapt
treatment
approach
adopt
patient
treatmentfailur
patient
prepar
earli
intub
invas
mechan
ventil
even
consid
extracorpor
membran
oxygen
ecmo
variabl
clinic
characterist
laboratori
paramet
treatment
approach
clinic
outcom
categor
variabl
measur
use
test
continu
variabl
measur
use
mannwhitney
u
test
nonsever
group
includ
mild
moder
patient
sever
group
statist
analys
conduct
use
r
statist
softwar
r
foundat
statist
comput
respect
patient
sever
group
lower
lymphocyt
count
cell
percentag
nonsever
group
sever
group
also
higher
level
nonsever
group
tabe
signific
differ
two
group
term
white
blood
cell
count
studi
develop
riskadapt
treatment
approach
accord
ill
sever
mild
moder
sever
studi
indic
use
riskadapt
treatment
approach
patient
associ
signific
clinic
manifest
allevi
clinic
imag
recoveri
patient
sever
earli
shortterm
use
lowdos
methylprednisolon
delay
rna
clearanc
influenc
igg
type
antibodi
product
compar
nonsever
patient
character
fever
dri
cough
fatigu
patient
symptom
nausea
vomit
diarrhea
etc
howev
clinic
practic
viral
infect
like
influenza
need
differenti
influenza
also
contagi
respiratori
ill
caus
influenza
virus
infect
upper
respiratori
tract
sometim
lung
main
symptom
influenza
sudden
high
fever
headach
myalgia
gener
malais
caus
mild
sever
ill
time
lead
death
studi
sever
patient
abnorm
hematolog
manifest
includ
signific
lower
lymphocyt
cell
increas
fibribogen
ddimer
fibrinfibrinogen
degrad
product
fdp
level
j
u
r
n
l
p
r
e
p
r
f
high
level
demonstr
cytokin
storm
might
exsit
clinic
studi
also
found
acut
cardiac
injuri
acut
renal
injuri
sever
patient
find
indic
system
diseas
pneumonia
howev
critic
influenza
may
also
caus
complic
high
morbid
mortal
pneumonia
myocard
central
nervou
system
diseas
death
situat
recommend
use
broadspectrum
molecular
diagnost
panel
rapid
detect
common
respiratori
pathogen
make
differenti
diagnosi
clinic
emerg
intens
care
unit
pneumonia
unknown
caus
accompani
lymphocytopenia
elev
level
obviou
abnorm
laboratori
parametr
clinician
ask
patient
famili
contact
histori
patient
nucleic
acid
detect
time
diagnosi
treatment
clinician
need
conduct
clinic
classif
base
patient
clinic
symptom
laboratori
test
result
includ
chest
ct
differ
clinic
type
indic
patient
differ
pathophysiolog
process
differ
stage
diseas
develop
therefor
requir
tailor
treatment
aproach
although
efficaci
antivir
therapi
still
uncertain
combin
treatment
base
inhibit
viral
replic
might
reduc
inflammatori
injuri
allow
bodi
gradual
produc
enough
virusspecif
antibodi
clear
viru
immun
respons
ultim
cure
diseas
great
debat
use
corticosteroid
coronaviru
infect
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
ryndrom
mer
data
system
corticosteroid
treatment
critic
lack
find
studi
support
use
corticosteroid
sever
earli
use
immedi
admiss
within
first
three
day
hospit
might
rel
rapid
control
diseas
progress
avoid
diseas
deterior
shortterm
lowdos
administr
methylprednisolon
day
could
avoid
corticosteroid
potenti
risk
hand
cortocosteroid
use
influenc
rna
clearanc
j
u
r
n
l
p
r
e
p
r
f
igg
antibodi
product
conclus
establish
riskadapt
treatment
strategi
strategi
could
consid
use
effici
approach
patient
base
shortterm
observ
howev
studi
certain
limit
retrospect
studi
singl
center
sampl
rel
small
observ
time
short
continu
evalu
riskadapt
treatment
strategi
need
research
receiv
extern
fund
ethic
approv
obtain
ethic
committe
first
affili
hospit
univers
scienc
technolog
china
retrospect
observ
studi
inform
consent
obtain
author
declar
conflict
interest
